

## **Kineta Scientists to Present Novel Antiviral Research Findings at International Conference**

### *Small Molecule Vaccine Adjuvant Compounds Activate RIG-I Innate Immune Pathway*

SEATTLE, WA, October 3, 2011 – Today, Kineta scientists will present new findings from the company’s antiviral drug development program – vaccine adjuvants of the Retinoic Acid Inducible Gene I (RIG-I), at the Fifth Annual International Society for Vaccines, Global Congress, in Seattle. Research scientist, Myra L. Wang, Ph.D. will offer the oral presentation on Kineta’s novel research program.

Dr. Wang plans to describe two of Kineta’s lead small molecules which induce the RIG-I gene response within the innate immune pathway. She will share data that demonstrate their potential as novel adjuvants that can be used in the development of newer and more effective vaccines.

“Presently there are few effective vaccine adjuvants. By focusing on compounds that activate the RIG-I pathway, Kineta is initiating a new era in which the host immune response is employed to both extend the duration of protection and boost the efficacy of therapeutic and preventative vaccines. Further, we anticipate far fewer side effects,” said Chief Scientific Officer and Executive Vice President, Shawn P. Iadonato, Ph.D.

Kineta’s RIG-I program also encompasses development of multiple antiviral small molecule drugs. Principal scientist, Kristen Bedard, Ph.D. will discuss this area of research at the conference with the presentation of a poster entitled, “Small molecule agonists of the RIG-I pathway and their potent immune pathway stimulation and broad antiviral actions.” These lead compounds have shown efficacy against multiple viruses including: influenza, hepatitis C, West Nile virus and numerous other viral pathogens.

Kineta is pleased to participate in the prestigious conference. The ISV Global Congress is an annual opportunity for leading scientists around the world to share their research with the goal of accelerating the development of vaccines for human benefit.

For more information on today’s announcement or to schedule interviews, contact Meg O’Conor, Director of Investor Relations and corporate communications, [moconor@kinetabio.com](mailto:moconor@kinetabio.com), 206-251- 8638.

#####

**Kineta, Inc.** is a Seattle-based privately held biotechnology company specializing in clinical advancement of drugs that modulate and enhance the human immune system. Our world class scientists are pioneers in developing life-changing classes of drugs that harness the power of the immune system to fight disease. Kineta seeks to improve the lives of millions of people suffering from autoimmune and viral diseases. Our progressive business model focuses on targeting unmet medical needs and rapid achievement of important clinical milestones. For more information on Kineta, Inc. visit our website, [www.Kinetabio.com](http://www.Kinetabio.com)

**NOTICE:**

This document contains certain forward-looking statements, including without limitation statements regarding Kineta's plans for preclinical studies and prospective FDA filings. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta's business which could significantly affect expected results, including without limitation progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.